Evenity®

Understanding Evenity® 

Evenity® (romosozumab-aqqg) is a monoclonal antibody used to treat osteoporosis in postmenopausal women at high risk for fractures. It is unique among osteoporosis treatments because it works by both increasing bone formation and decreasing bone resorption. This dual action makes Evenity® a fast-acting option for improving bone density and reducing fracture risk, particularly for high-risk patients who need rapid bone-building therapy.

How Evenity® Works:

• Stimulates new bone formation while simultaneously reducing bone loss.
• Increases bone density, strengthening bones and reducing fracture risk.
• Provides a rapid-acting solution for patients at high risk for osteoporosis-related fractures.

FDA Approval:

• Evenity® (romosozumab-aqqg): Approved in 2019.

For more information, please visit the Evenity® patient website and speak with your healthcare provider to determine if Evenity® is the right treatment option for you.